{"id":879756,"date":"2025-08-27T16:15:10","date_gmt":"2025-08-27T20:15:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/"},"modified":"2025-08-27T16:15:10","modified_gmt":"2025-08-27T20:15:10","slug":"rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/","title":{"rendered":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Aug.  27, 2025  (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that\u00a0David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences:<\/p>\n<ul type=\"disc\">\n<li>Wells Fargo Healthcare Conference on\u00a0Wednesday, September 3, 2025\u00a0at\u00a09:30 a.m. ET<\/li>\n<li>Morgan Stanley\u00a0Global Healthcare Conference on\u00a0Tuesday, September 9, 2025\u00a0at\u00a011:30 a.m. ET<\/li>\n<\/ul>\n<p>The fireside chats will be webcasted and available under \u201cEvents &amp; Presentations\u201d in the Investor Relations section of the Company\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sFaMPdxC50357qjhOgOUu7tBYOvNK8FeTV96J5qfTes-W95Phl6WlrT03cSMl3SxNjCTfJDOKMWKcJap8x9erk1ayJmOAtAgc7TqoLXCpDc=\" rel=\"nofollow\" target=\"_blank\">www.rhythmtx.com<\/a>, and webcast replays will be available for 30 days following the presentations.<\/p>\n<p>\n        <strong>About Rhythm Pharmaceuticals<\/strong><br \/>\n        <br \/>Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm\u2019s lead asset, IMCIVREE<sup>\u00ae<\/sup> (setmelanotide), an MC4R agonist is approved by the FDA to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin\/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the European Commission (EC) and the UK\u2019s Medicines &amp; Healthcare Products Regulatory Agency (MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm\u2019s headquarters is in Boston, MA.<\/p>\n<p>\n        <strong>Setmelanotide Indication<\/strong><br \/>\n        <br \/>In\u00a0the United States, setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin\/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS).<\/p>\n<p>In the\u00a0European Union\u00a0and the\u00a0United Kingdom, setmelanotide is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. In the\u00a0European Union\u00a0and the\u00a0United Kingdom, setmelanotide should be prescribed and supervised by a physician with expertise in obesity with underlying genetic etiology.<\/p>\n<p>\n        <strong>Limitations of Use<\/strong>\n      <\/p>\n<p>Setmelanotide is not indicated for the treatment of patients with the following conditions as setmelanotide would not be expected to be effective:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:13.5pt;margin-bottom:13.5pt\">Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign<\/li>\n<li style=\"margin-top:13.5pt;margin-bottom:13.5pt\">Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity<\/li>\n<\/ul>\n<p>\n        <strong>CONTRAINDICATION<\/strong>\n      <\/p>\n<p>Prior serious hypersensitivity to setmelanotide or any of the excipients in IMCIVREE. Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported.<\/p>\n<p>\n        <strong>WARNINGS AND PRECAUTIONS<\/strong>\n      <\/p>\n<p>\n        <strong>Disturbance in Sexual Arousal:\u00a0<\/strong>Spontaneous penile erections in males and sexual adverse reactions in females have occurred. Inform patients that these events may occur and instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.<\/p>\n<p>\n        <strong>Depression and Suicidal Ideation:\u00a0<\/strong>Depression, suicidal ideation and depressed mood have occurred. Monitor patients for new onset or worsening depression or suicidal thoughts or behaviors. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors, or clinically significant or persistent depression symptoms occur.<\/p>\n<p>\n        <strong>Hypersensitivity Reactions:\u00a0<\/strong>Serious hypersensitivity reactions (e.g., anaphylaxis) have been reported. If suspected, advise patients to promptly seek medical attention and discontinue IMCIVREE.<\/p>\n<p>\n        <strong>Skin Hyperpigmentation, Darkening of Pre-existing\u00a0Nevi, and Development of New Melanocytic Nevi:\u00a0<\/strong>Generalized or focal increases in skin pigmentation, darkening of pre-existing nevi, development of new melanocytic nevi and increase in size of existing melanocytic nevi have occurred. Perform a full body skin examination prior to initiation and periodically during treatment to monitor pre-existing and new pigmented lesions.<\/p>\n<p>\n        <strong>Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants:\u00a0<\/strong>IMCIVREE is not approved for use in neonates or infants. Serious and fatal adverse reactions including \u201cgasping syndrome\u201d can occur in neonates and low birth weight infants treated with benzyl alcohol preserved drugs.<\/p>\n<p>\n        <strong>ADVERSE REACTIONS<\/strong>\n      <\/p>\n<p>Most common adverse reactions (incidence \u226520%) included skin hyperpigmentation, injection site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression, and spontaneous penile erection.<\/p>\n<p>\n        <strong>USE IN SPECIFIC POPULATIONS<\/strong>\n      <\/p>\n<p>Treatment with IMCIVREE is not recommended when breastfeeding. Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus.<\/p>\n<p>To report SUSPECTED ADVERSE REACTIONS, contact\u00a0Rhythm Pharmaceuticals\u00a0at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IfwmbA9C8kZPiAqKP0UKEF6U6F9Sqa5f3vJrEbVS_dYSHSZdyJnMwqv7JfUzOZOhSC5DyhX1knPCgNoHzIk3uyQp8yl_xAORM84Q4U_iElepGdMwx0D83A1_RwgBsjjmLb145jbNTuE3UrPhtOY2S3VsWpOWISlyImPWkaDb_LFRMCdP03u_OIZzQLp_wnkj-bOpzyATKgAbUWPtfeiJiv4NyKf3H5cc-uASuCGmWtJNQWd_JyRnMmEq4XPpTZTcgvfBNSo4HikZixXIdoTZePpqb2RmyTgzNubCK0ys95ZyCMOZxkUQDkrvE3Ds5O-a\" rel=\"nofollow\" target=\"_blank\"><u>http:\/\/www.fda.gov\/medwatch<\/u><\/a>. See section 4.8 of the\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sWmEJbHXoJ2e2hcznrWJQ-C654tdhRP6UA3GA1aWw4HtJmmVG7Aqd-PYJrYCZ36Pkx8RmQELanxJaYcW_aqpJLD-7soyRy7rjsPmeqgugP6s0plyBsGUDHbH7REe3w_F1IgA77sSLdFb-qmG1J0qutfZ-giDzEkD3BN2uPvBptPqiR3iW_xaGDuPGiR9QPeFBT6jFZA4iC6VVe2IG64owsPsSPK75GNyQAI5w_KkyG6EMpKhuqNHU7-PWsT4b0VjmiN3LqBlaYwudxsdwKtI9X3bfWqKU_9wiWICi_gGgXQHfIDgU47R-05rjGWi6wxmTjpSzvd50YWhr4ObRwpLUYTgC947vfZGb690if8np3UK_g2Tv1uY1qYVpbOrCq7I4T-2T9q93Wc-9CQ2lAdAaRgwIlPhTchGGQ4UzCQSpkXidVWOm5k2_oTJxZsS3cl8kG6Dq_JumOqEgWzk73xIRw==\" rel=\"nofollow\" target=\"_blank\"><u>Summary of Product Characteristics<\/u><\/a>\u00a0for information on reporting suspected adverse reactions in\u00a0Europe.<\/p>\n<p>\n        <strong>Please see the full Prescribing Information for additional Important Safety Information.<\/strong>\n      <\/p>\n<p>\n        <strong>About\u00a0Rhythm Pharmaceuticals<\/strong><br \/>\n        <br \/>Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. Rhythm\u2019s lead asset, IMCIVREE<sup>\u00ae<\/sup>\u00a0(setmelanotide), an MC4R agonist designed to treat hyperphagia and severe obesity, is approved by the FDA to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin\/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. Both the\u00a0European Commission\u00a0(EC) and the UK\u2019s\u00a0Medicines &amp; Healthcare Products Regulatory Agency\u00a0(MHRA) have authorized setmelanotide for the treatment of obesity and the control of hunger associated with genetically confirmed BBS or genetically confirmed loss-of-function biallelic POMC, including PCSK1, deficiency or biallelic LEPR deficiency in adults and children 2 years of age and above. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare diseases, as well as investigational MC4R agonists bivamelagon and\u00a0RM-718, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. Rhythm\u2019s headquarters is in\u00a0Boston, MA.<\/p>\n<p>\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the safety, efficacy, potential benefits of, and clinical design or progress of any of our products or product candidates at any dosage or in any indication, our participation in upcoming events and presentations, and the date, time and content thereof and the timing of any of the foregoing.\u00a0Statements using words such as \u201cexpect\u201d, \u201canticipate\u201d, \u201cbelieve\u201d, \u201cmay\u201d, \u201cwill\u201d and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our ability to enroll patients in clinical trials, the design and outcome of clinical trials, the impact of competition, the ability to achieve or obtain necessary regulatory approvals, risks associated with data analysis and reporting, unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and regulations governing our international operations and the costs of any related compliance programs, our ability to successfully commercialize setmelanotide, our liquidity and expenses, our ability to retain our key employees and consultants, and to attract, retain and motivate qualified personnel, and general economic conditions, and the other important factors, including those discussed under the caption \u201cRisk Factors\u201d in Rhythm\u2019s Quarterly Report on Form 10-Q for the three months ended\u00a0June 30, 2025\u00a0and our other filings with the\u00a0Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this press release or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise.<\/p>\n<p>\n        <strong>Corporate Contact:<\/strong><br \/>\n        <br \/>David Connolly<br \/>Head of Investor Relations and Corporate Communications<br \/>Rhythm Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5-QFOtFQT5EEgVzzapEENLxUmZXtzJc6fHlfPv5W4KtautDU1AoUEEQZWluOx1mqp1aa5_RS8RkwlBDqafDQTupIii8BbqQAPKkQGEdxLx8QhWrR0sP1ech3Inoi-1S8HtpSFt6ocMwd4nUrDfZ1jUK3swZUc5QM0zJv5bRo6xJDBiASPQImHIf52B8jV1m8y9lV2iUwy0y-blHG0xHtUggG7Z4kcU7dlYNJXv_ue1BwPdLfJcX_2TcdPkfvh49TX2ZofkmpuaUmMrTP8VUH-w==\" rel=\"nofollow\" target=\"_blank\"><u>dconnolly@rhythmtx.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Layne Litsinger<br \/>Real Chemistry<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uURkQLBj9KE8O1rjFKnUm2ToN6xvx0yPm45bg2kwTR-pDJdAnVQI36zPJexs50Bcwx4dSDxSO0TsOojFhduPfbOZHWjRa7kj1-KEoDP2TMdyHaf6nvQTwm1QARcJqg6ahH1W4DdQ-oi4kCtv-jQvJudO-CQmjtOB_8dG4VRuBiQUBgvb4m-zqYsMsvZLg0ZcTDYRGT4UH_BKBM_q-oFw6GtTvqDAOJLrvtG4a6rDIBqnhajrbow8yjKxURBxgcd9pAPQSPOPNs7yZgOhWn6B3cpSkWsbDB0lV-Gb6DftpNweyJoVI6PNdbMLdArPgNdJ\" rel=\"nofollow\" target=\"_blank\"><u>llitsinger@realchemistry.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/Y2ZlMDU1NmItNGY3My00ZWYzLTgyOWQtOTU3NDRiOTJjNTYzLTEwMjI3NzctMjAyNS0wOC0yNy1lbg==\/tiny\/Rhythm-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that\u00a0David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences: Wells Fargo Healthcare Conference on\u00a0Wednesday, September 3, 2025\u00a0at\u00a09:30 a.m. ET Morgan Stanley\u00a0Global Healthcare Conference on\u00a0Tuesday, September 9, 2025\u00a0at\u00a011:30 a.m. ET The fireside chats will be webcasted and available under \u201cEvents &amp; Presentations\u201d in the Investor Relations section of the Company\u2019s website at\u00a0www.rhythmtx.com, and webcast replays will be available for 30 days following the presentations. About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-879756","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that\u00a0David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences: Wells Fargo Healthcare Conference on\u00a0Wednesday, September 3, 2025\u00a0at\u00a09:30 a.m. ET Morgan Stanley\u00a0Global Healthcare Conference on\u00a0Tuesday, September 9, 2025\u00a0at\u00a011:30 a.m. ET The fireside chats will be webcasted and available under \u201cEvents &amp; Presentations\u201d in the Investor Relations section of the Company\u2019s website at\u00a0www.rhythmtx.com, and webcast replays will be available for 30 days following the presentations. About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients &hellip; Continue reading &quot;Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-27T20:15:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences\",\"datePublished\":\"2025-08-27T20:15:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/\"},\"wordCount\":1395,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/\",\"name\":\"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=\",\"datePublished\":\"2025-08-27T20:15:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Market Newsdesk","og_description":"BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) &#8212; Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that\u00a0David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences: Wells Fargo Healthcare Conference on\u00a0Wednesday, September 3, 2025\u00a0at\u00a09:30 a.m. ET Morgan Stanley\u00a0Global Healthcare Conference on\u00a0Tuesday, September 9, 2025\u00a0at\u00a011:30 a.m. ET The fireside chats will be webcasted and available under \u201cEvents &amp; Presentations\u201d in the Investor Relations section of the Company\u2019s website at\u00a0www.rhythmtx.com, and webcast replays will be available for 30 days following the presentations. About Rhythm Pharmaceuticals Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients &hellip; Continue reading \"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-27T20:15:10+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences","datePublished":"2025-08-27T20:15:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/"},"wordCount":1395,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/","name":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=","datePublished":"2025-08-27T20:15:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTE3NiM3MTE4NDk0IzIwMTEyMDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/rhythm-pharmaceuticals-announces-participation-in-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/879756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=879756"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/879756\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=879756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=879756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=879756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}